Mortality risk in current and new antipsychotic AD users: Large scale Japanese study

Heii Arai, Yu Nakamura, Masamoto Taguchi, Hiroyuki Kobayashi, Keita Yamauchi, Lon S. Schneider

Research output: Contribution to journalArticle

10 Citations (Scopus)


Introduction: We studied the mortality risk of long term and new antipsychotic drug use in Alzheimer's disease (AD) patients in Japan to determine improved treatment protocols. Methods: This 24-week prospective cohort study included 10,079 Japanese AD patients (female, 69%; average age, 81 years) under routine clinical care in 357 medical sites. The antipsychotic medication history was varied (63.7% were long-term users). Mortality rates and odds ratio were analyzed (initial 10 weeks and from 11-24 weeks). Results: The antipsychotic exposed group with shorter treatment periods had a higher mortality risk compared to controls. The newly prescribed users (antipsychotic treatment started during the follow-up) showed increased mortality (9.4% during the 11-24 week period). Conclusions: New use of antipsychotic drugs represents a distinct risk for mortality; those on long-term antipsychotic therapy seem to be at less risk. The warning issued 10 years earlier on antipsychotics use for AD patients should be reviewed.

Original languageEnglish
JournalAlzheimer's and Dementia
Publication statusAccepted/In press - 2016



  • Alzheimer's disease
  • Antipsychotics
  • Dementia
  • Mortality risk
  • Prospective cohort study

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this